Melane Sampson, Author at BioTuesdays

Developments

Olema reports compelling preclinical data on OP-3136’s anti-tumor activity

Olema Oncology (NASDAQ:OLMA) has announced results from three preclinical studies demonstrating the robust anti-tumor activity of OP-3136 as a single agent and in combination with palazestrant. The results will be...

October 23, 2024

Developments

DSMB approves second phase of Ocugen’s GARDian trial for Stargardt disease

Ocugen (NASDAQ:OCGN) has announced that the Data and Safety Monitoring Board (DSMB) has approved enrollment for the second phase of its Phase 1/2 clinical trial of OCU410ST GARDian for Stargardt disease. The GARDian...

October 22, 2024

Developments

SIGA signs licencing agreement with Vanderbilt U for mAbs portfolio

SIGA Technologies (NASDAQ:SIGA) announced that it has entered into an agreement with Vanderbilt University to license to a portfolio of preclinical, fully human monoclonal antibodies (mAbs), which have the potential...

October 22, 2024

Developments

MOBILion reveals next-gen high-res mass spec approach poised to disrupt industry

Closely-held MOBILion Systems has announced a novel, next-generation high-resolution mass spectrometry approach for complex sample analysis, delivering unprecedented speed, sensitivity, specificity, and quantitative...

October 21, 2024

Developments

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

Zymeworks (NASDAQ:ZYME) has announced that the first patient has been dosed in its global first-in-human Phase 1 clinical study to evaluate the safety and tolerability of ZW171 for the treatment of ovarian cancer, non...

October 21, 2024

Developments

IJS publishes PolyPid’s Phase 3 results of D-PLEX for preventing SSIs in colorectal surgery

PolyPid (NASDAQ:PYPD) has announced the publication of a study in the International Journal of Surgery (IJS), showcasing the full data set from its Phase 3 SHIELD I trial of D-PLEX, focused on preventing surgical site...

October 21, 2024

Developments

Celularity expands portfolio acquiring Rebound from Sequence

Celularity (NASDAQ:CELU) has announced its acquisition of Rebound from Sequence LifeScience, expanding its commercial portfolio of placental-derived advanced biomaterial products. Rebound is a full thickness placental...

October 17, 2024

Developments

EC grants orphan medicinal product designation of Theriva’s VCN-01 for retinoblastoma

Theriva Biologics (NYSE American:TOVX) has announced that the European Commission (EC) has adopted the European Medicines Agency’s (EMA) recommendation to grant orphan medicinal product designation to its lead...

October 16, 2024

Executive Moves

Lake Street Captial Markets names Alex Nowak as director investment banking

Alex Nowak has joined Lake Street Capital Markets’ growing banking team as director of the healthcare investment banking practice. In his new role, Mr. Nowak will focus on expanding client relationships and supporting...

October 15, 2024

Feature

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

Closely-held Creyon Bio is developing a faster, more cost-effective path to new medicines for rare and common diseases through the AI-enabled engineering of oligonucleotide-based therapies (OBMs) that deliver safe...

October 15, 2024

Author - Melane Sampson

Olema reports compelling preclinical data on OP-3136’s anti-tumor activity

DSMB approves second phase of Ocugen’s GARDian trial for Stargardt disease

SIGA signs licencing agreement with Vanderbilt U for mAbs portfolio

MOBILion reveals next-gen high-res mass spec approach poised to disrupt industry

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

IJS publishes PolyPid’s Phase 3 results of D-PLEX for preventing SSIs in colorectal surgery

Celularity expands portfolio acquiring Rebound from Sequence

EC grants orphan medicinal product designation of Theriva’s VCN-01 for retinoblastoma

Lake Street Captial Markets names Alex Nowak as director investment banking

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

General

More